A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen or two different epitopes on the same antigen. [1]

Feb 19, 2025 · Bispecific antibodies (bsAbs) represent a significant advancement in precision medicine, with 11 bsAb products approved by the FDA as of December 2023.

In this paper, we elaborate on the classic platforms, mechanisms, and applications of BsAbs. We hope that this review can stimulate new ideas for the development of BsAbs and improve …

Mar 6, 2024 · Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic applications that cannot be achieved using conventional IgG-based antibodies.

Bispecific antibodies are lab-created proteins given intravenously that mimic the body’s natural antibodies. Unlike regular antibodies, which only bind to a single antigen, bispecific antibodies …

Aug 29, 2024 · Bispecific antibodies (bsAbs) offer a novel approach to anticancer therapy by targeting different antigens via a range of mechanisms of action. Manipulating bsAb structures …

Bispecific antibodies (BsAbs) have two distinct binding domains that can bind to two antigens or two epitopes (an antigen part) of the same antigen simultaneously.

Bispecific antibodies (bsAbs) are molecules containing anti-body-derived fragments able to bind two different antigen epitopes with high specificity.

Nov 5, 2024 · After 2 decades of research, bispecific antibodies (BsAbs) are an emerging treatment option for several hematologic malignancies. BsAbs are administered in multiple …

Bispecific antibody (BsAb) is one kind of the next generation of antibody. The dual targeting is a particular concept linked with bsAbs, enabling them to target two different antigens on two …